Nikolaos Papagiannakis,Hui Liu,Christos Koros,Athina‐Maria Simitsi,Maria Stamelou,Matina Maniati,Elena Buena‐Atienza,Chrysoula Kartanou,Georgia Karadima,Periklis Makrythanasis,Giannis Vatsellas,Enza Maria Valente,Thomas Gasser,Leonidas Stefanis

Abstract:Introduction Pathogenic variants in parkin (PRKN gene) are the second most prevalent known monogenic cause of Parkinson's disease (PD). How monoallelic or biallelic pathogenic variants in the PRKN gene may affect its transcription in patient‐derived biological material has not been systematically studied. Methods PRKN mRNA expression levels were measured with real‐time polymerase chain reaction (RT‐PCR) in peripheral blood mononuclear cells (PBMCs). PBMCs were derived from PRKN‐mutated PD patients (PRKN‐PD) (n = 12), sporadic PD (sPD) (n = 21) and healthy controls (n = 21). Six of the PRKN‐PD patients were heterozygous, four were compound heterozygous, and two were homozygous for PRKN variants. Results A statistically significant decrease in PRKN expression levels was present, compared to healthy controls and sPD, in heterozygous (P = 0.019 and 0.031 respectively) and biallelic (P

Parkin mRNA Expression Levels in Peripheral Blood Mononuclear Cells in Parkin‐Related Parkinson's Disease